碳酸镁
镁补充剂已被用于一项小规模 CPP 关节炎试验中,并略有成功。[50]Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis. 1983;42(suppl 1):106-107.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1047100/pdf/annrheumd00249-0113.pdf
羟氯喹
据报道,它对慢性 CPP 关节炎有效。通常比较安全且耐受性好。对于部分患者,它可能会降低炎症发作的频率或严重程度。[51]Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997 May;23(5):327-31.http://www.ncbi.nlm.nih.gov/pubmed/9195122?tool=bestpractice.com症状改善:低质量证据表明羟氯喹适度改善了很可能或可能为焦磷酸钙沉积症患者的症状。[51]Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997 May;23(5):327-31.http://www.ncbi.nlm.nih.gov/pubmed/9195122?tool=bestpractice.com低质量的观察性(队列)研究或者受试者<200名且方法学存在缺陷的随机对照临床试验(RCT)。
甲氨蝶呤
可能对治疗多关节炎症性 CPP 关节炎患者有一定作用。[52]Chollet-Janin A, Finckh A, Dudler J, et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007 Feb;56(2):688-92.http://onlinelibrary.wiley.com/doi/10.1002/art.22389/fullhttp://www.ncbi.nlm.nih.gov/pubmed/17265505?tool=bestpractice.com然而,在 CPPD 关节病患者中进行的一项小规模、双盲、交叉试验表明,与安慰剂相比,甲氨蝶呤并未显著改善疾病活动度。[53]Finckh A, Mc Carthy GM, Madigan A, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014 Oct 15;16(5):458.http://www.arthritis-research.com/content/16/5/458http://www.ncbi.nlm.nih.gov/pubmed/25315665?tool=bestpractice.com
抗白细胞介素 1(抗 IL-1)分子
尽管没有充足的数据来完全评估除类风湿关节炎以外炎症性疾病患者中抗 IL-1 分子的疗效和安全性,但是新数据结果是令人鼓舞的。[54]Moltó A, Olivé A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine. 2010 Mar;77(2):102-7.http://www.ncbi.nlm.nih.gov/pubmed/20045371?tool=bestpractice.com